Last updated on April 20, 2014 at 21:20 EDT

Latest Chiasma (pronounced key-az-ma) Inc. Stories

2013-02-18 08:23:10

BASEL, Switzerland, NEW YORK and JERUSALEM, Feb. 18, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-az-ma) Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreolin is an investigational oral form of the peptide octreotide, a somatostatin analog that is...